Type 2 diabetes
Conditions
Interventions
Miglipidol treatment group:Miglitol 50mg tid, oral
Acarbose mimetic tablets, 50mg tid, oral
Acarbose treatment group:Acarbose 50mg tid, oral
Miglitol simulating tablets, 50mg tid, oral
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 74 Years
Inclusion criteria
Inclusion criteria: 1. Sign an informed consent form prior to any research procedure; 2. Diagnosis of type 2 diabetes (WHO 1999); 3. Those who have not received any hypoglycemic treatment or have had short-term hypoglycemic treatment (=18 and 7.5% and =24 and <35 kg/m2.
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant or breast-feeding, women who are pregnant and do not take appropriate methods of contraception to avoid pregnancy; 2. Have the following medical history: 1. Type 1 diabetes, pancreatic damage caused by diabetes or acromegaly or Cushing's syndrome with the following lesions; 2. Acute Complications of Diabetes: A history of ketoacidosis or hyperosmolar nonketotic coma has occurred in the past 6 months; 3. Uncontrolled high blood pressure, systolic blood pressure >=180 mmHg and / or diastolic blood pressure >=120mmHg; 4. Those with obvious blood system diseases, hemoglobin 194.5 mmol / L or K + > 5.5 mmol/L) within 4 weeks prior to screening or examination; 9. New York Heart Association (NYHA) grade III or IV congestive heart failure; 10. A significant history of cardiovascular disease in the past 3 months, defined as: myocardial infarction, coronary angioplasty or bypass surgery, valvular disease or repair, unstable angina, transient ischemic attack, or cerebrovascular accident; 11. History of gastrointestinal diseases: gastrointestinal anastomosis, intestinal resection, severe bowel, intestinal obstruction and intestinal ulcer; 12. Hereditary history of galactose intolerance, Lapp lactase deficiency and glucose-galactose malabsorption; 13. Have been diagnosed with a malignant tumor or have been treated for the past 5 years; 14. History of organ transplantation or acquired immunodeficiency syndrome (AIDS); 15. A history of alcohol abuse or drug abuse in the past 12 months; 16. Potentially unreliable patients and those patients who were judged to be unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c; | — |
Secondary
| Measure | Time frame |
|---|---|
| PPG;TG;Tch;VFA;INS;C-peptide;Glucagon;GLP-1;BMI; | — |
Countries
China
Contacts
Public ContactLi Chen
Qilu Hospital of Shandong University
Outcome results
None listed